Repeat Oral Dose SCY-247 Exceeds Exposures Associated with Efficacy in Murine Models of Invasive Candidiasis with Low Potential for Drug-Drug Interactions with Key CYP450s

A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease. – PXL 770

PXL770, a direct AMPK activator, shows favorable cardiac safety profile

PXL770, a direct AMPK activator for the treatment of NASH, shows a favorable PK, tolerability and safety profile in humans

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo- controlled, phase 2a study Kenneth Cusi, Naim Alkhouri, Stephen A Harrison, Pascale Fouqueray, David E Moll

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non- alcoholic fatty liver disease: A phase 1b study – PXL770

Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy

Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis – PXL770

A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant OPEN Polycystic Kidney Disease – SCY 770

In vitro Efficacy of Second-Generation Triterpenoid Antifungal, SCY-247, against Multidrug- and Pandrug-resistant Candida auris